WilmerHale Represents PerkinElmer in $5.25B Acquisition of BioLegend

WilmerHale Represents PerkinElmer in $5.25B Acquisition of BioLegend

Client News

On July 26, 2021, PerkinElmer, a global leader committed to innovating for a healthier world, announced it has entered into an agreement to acquire BioLegend, a leading provider of life science antibodies and reagents, for $5.25 billion in a combination of cash and stock. The transaction will be the largest in PerkinElmer’s history and is expected to close by the end of the 2021 calendar year, subject to regulatory approvals and other customary closing conditions.

BioLegend provides its academic and biopharmaceutical customers with best-in-class antibodies and reagents in high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant proteins, magnetic cell separation and bioprocessing, and has more than 700 employees with estimated 2022 revenues of $380 million. Upon joining PerkinElmer, BioLegend will expand PerkinElmer’s existing life science franchise into new segments, and its state-of-the-art campus in San Diego will become PerkinElmer’s global Center of Excellence for research reagent content development for the combined company.

The WilmerHale team advising PerkinElmer was led by Hal Leibowitz with support from Andrew Bonnes, Jeffries Oliver-Li and Chris Gravallese on corporate and M&A matters. The team also included Steven Barrett on technology and licensing matters; Justin Ochs, Erika Robinson and Nathan Moore on financing matters; Amy Null and Scott Kilgore on benefits matters; Julie Hogan Rodgers, Bill Caporizzo, Meghan Walsh and Gavin Tullis on tax matters; and Barry Hurewitz on regulatory matters.


Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.